Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Research Report 2024
The Dipeptidyl Peptidase IV (DPP-IV) inhibitors market refers to the industry that focuses on the production and distribution of medications known as DPP-IV inhibitors. DPP-IV inhibitors are a class of oral antidiabetic drugs used in the treatment of type 2 diabetes mellitus. They work by inhibiting the action of the enzyme DPP-IV, which leads to increased levels of incretin hormones and improved glycemic control.
According to Mr Accuracy reports new survey, global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market is projected to reach US$ 18170 million in 2029, increasing from US$ 11200 million in 2022, with the CAGR of 7.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market research.
The DPP-IV inhibitors market is a segment within the broader pharmaceutical industry, specifically in the field of diabetes management. It involves the development, manufacturing, and distribution of DPP-IV inhibitor medications used to treat type 2 diabetes.
The DPP-IV inhibitors market is influenced by factors such as the increasing prevalence of type 2 diabetes worldwide, the rising demand for effective oral antidiabetic medications, and the growing emphasis on diabetes management and control. Additionally, factors such as an aging population, sedentary lifestyles, and changes in dietary habits contribute to the market's growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AstraZeneca
Boehringer
Eli Lilly
Merck
Mitsubishi Tanabe Pharma
Novartis
Takeda
Segment by Type
Sitagliptin
Vildagliptin
Saxagliptin
Linagliptin
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Dipeptidyl Peptidase IV (DPP-IV) Inhibitors report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market is projected to reach US$ 18170 million in 2029, increasing from US$ 11200 million in 2022, with the CAGR of 7.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market research.
The DPP-IV inhibitors market is a segment within the broader pharmaceutical industry, specifically in the field of diabetes management. It involves the development, manufacturing, and distribution of DPP-IV inhibitor medications used to treat type 2 diabetes.
The DPP-IV inhibitors market is influenced by factors such as the increasing prevalence of type 2 diabetes worldwide, the rising demand for effective oral antidiabetic medications, and the growing emphasis on diabetes management and control. Additionally, factors such as an aging population, sedentary lifestyles, and changes in dietary habits contribute to the market's growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AstraZeneca
Boehringer
Eli Lilly
Merck
Mitsubishi Tanabe Pharma
Novartis
Takeda
Segment by Type
Sitagliptin
Vildagliptin
Saxagliptin
Linagliptin
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Dipeptidyl Peptidase IV (DPP-IV) Inhibitors report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source